Table 2.

Proportion of Participants With Plasma HIV-1 RNA ≤10 000 Copies/mL at 48 Weeks Controlling for Baseline Plasma HIV-1 RNA*

Baseline Plasma HIV-1 RNA
≤10 000 Copies/mL
Baseline Plasma HIV-1 RNA
>10 000 Copies/mL
All Participants
ABC/3TC/ZDV3TC/ZDVABC/3TC/ZDV3TC/ZDVABC/3TC/ZDV3TC/ZDV
Intent-to-treat analyses:
Switch-failure14/18 (78)18/25 (72)24/84 (29)9/78 (12)37/102 (36)27/103 (26)
P= .77P = .008P = .014
Switch-included14/18 (78)19/25 (76)33/84 (39)22/78 (28)47/102 (46)41/103 (40)
P= .96P = .14 P = .18
As-treated analysis13/14 (93)17/21 (81)21/38 (55)9/20 (45)34/52 (65)26/41 (63)
P= .47P = .35 P = .25
  • * Values in parentheses are %. P values comparing the % among treatment groups are provided.